CIC
RUBY

Cornercap Investment Counsel’s Rubius Therapeutics, Inc RUBY Stock Holding History

Cornercap Investment Counsel’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-256,194
Closed -$111K – 659
2022
Q3 		$111K Buy
256,194
+190,790
+292% +$143K 0.02% 523
2022
Q2 		$56K Buy
+65,404
New +$110K 0.01% 537

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cornercap Investment Counsel's RUBY Position: Q4 2022 in Review

Cornercap Investment Counsel sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 256,194 shares — an estimated $111K sold.

Cornercap Investment Counsel first reported a position in RUBY in Q2 2022 and held it in 2 quarters. The position peaked at $111K in Q3 2022. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Cornercap Investment Counsel reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Cornercap Investment Counsel sold 256,194 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $111K.
  • Cornercap Investment Counsel first reported a position in Rubius Therapeutics, Inc in Q2 2022 and held it in 2 quarters.
  • Cornercap Investment Counsel's Rubius Therapeutics, Inc position peaked at $111K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Cornercap Investment Counsel's 13F filing for Q4 2022, filed 13 Feb 2023.